<bill session="117" type="h" number="9297" updated="2023-08-14T21:00:32Z">
  <state datetime="2022-11-15">REFERRED</state>
  <status>
    <introduced datetime="2022-11-15"/>
  </status>
  <introduced datetime="2022-11-15"/>
  <titles>
    <title type="display">Pre-Approval Information Exchange Act of 2022</title>
    <title type="short" as="introduced">Pre-Approval Information Exchange Act of 2022</title>
    <title type="official" as="introduced">To amend the Federal Food, Drug, and Cosmetic Act to facilitate the exchange of certain product information, and for other purposes.</title>
  </titles>
  <sponsor bioguide_id="G000558"/>
  <cosponsors>
    <cosponsor bioguide_id="B001248" joined="2022-11-15"/>
    <cosponsor bioguide_id="E000215" joined="2022-11-15"/>
    <cosponsor bioguide_id="G000568" joined="2022-11-15"/>
    <cosponsor bioguide_id="M001163" joined="2022-11-15"/>
    <cosponsor bioguide_id="P000608" joined="2022-11-15"/>
  </cosponsors>
  <actions>
    <action datetime="2022-11-15">
      <text>Introduced in House</text>
    </action>
    <action datetime="2022-11-15" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2022-11-16">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="117" type="h" number="7667" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
  </subjects>
  <amendments/>
  <summary date="2023-08-14T20:47:46Z" status="Introduced in House">Pre-Approval Information Exchange Act of 2022

This bill specifies that product information that is exchanged between drug manufacturers and certain health care entities (e.g., formulary committees) about drug products before regulatory approval is not considered to be misbranding if it relates to the product's investigational use and meets other specified criteria. The Government Accountability Office must study the use and effects of such information.</summary>
</bill>
